Vident Advisory LLC Buys Shares of 1,750 Ascendis Pharma A/S $ASND

Key Points

• Vident Advisory LLC has acquired a new stake in Ascendis Pharma A/S, purchasing 1,750 shares valued at approximately $273,000.
• Other institutional investors, such as T. Rowe Price and Invesco, have also increased their holdings in Ascendis Pharma A/S during the first quarter of the year.
• Ascendis Pharma reported a quarterly EPS of ($0.93), surpassing analysts' expectations, with revenue reaching $216.28 million for the same period.

Vident Advisory LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,750 shares of the biotechnology company's stock, valued at approximately $273,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after acquiring an additional 328,278 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Ascendis Pharma A/S by 0.6% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company's stock valued at $292,692,000 after acquiring an additional 10,366 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Ascendis Pharma A/S by 3.7% during the 1st quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company's stock valued at $186,795,000 after acquiring an additional 42,465 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after acquiring an additional 270,000 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Ascendis Pharma A/S by 13.5% during the 1st quarter. American Century Companies Inc. now owns 462,171 shares of the biotechnology company's stock valued at $72,034,000 after acquiring an additional 54,877 shares in the last quarter.

Ascendis Pharma A/S Price Performance

ASND stock opened at $202.90 on Wednesday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $208.16. The company has a 50-day moving average of $183.95 and a two-hundred day moving average of $168.66. The stock has a market capitalization of $12.42 billion, a price-to-earnings ratio of -39.32 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ASND shares. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, August 19th. Stifel Nicolaus boosted their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a "buy" rating in a report on Friday, August 8th. Cantor Fitzgerald raised their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Citigroup reiterated a "buy" rating and issued a $290.00 price objective (up from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Cowen reiterated a "buy" rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $244.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.